Fulford (India) Ltd - Stock Valuation and Financial Performance

BSE: 506803 | NSE: FULFORD | Trading | Small Cap

BSE Share Price
Not Listed

DeciZen - make an informed investing decision on Fulford India

M-Cap below 100cr DeciZen not available

Fulford (India) stock performance -

mw4me loader
P/E Ratio (SA):
32.51
Market Cap:
921.2 Cr.
52-wk low:
2,350
52-wk high:
2,363

Is an attractive stock to invest in?

1. Is a good quality company?

Data is not available for this company.

2. Is undervalued or overvalued?

No data found

3. Is a good buy now?

No data found

10 Year X-Ray of Fulford India:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.

Value Creation

Value Creation Index Colour Code Guide

Dec'10Dec'11Dec'12Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20TTM
ROCE % 6.8%3.4%-3.1%3.5%1.6%-9.9%12.3%11%15.2%13.5%-
Value Creation
Index
-0.5-0.8-1.2-0.8-0.9-1.7-0.1-0.20.10.0-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 19021421521621715814412399.7109109
Sales YoY Gr.-12.6%0.6%0.2%0.6%-27.3%-8.8%-14.5%-19%9.7%-
Adj EPS 24.712.9-11.89.15.9-36.445.445.571.272.772.7
YoY Gr.--47.6%-191.4%NA-34.4%-713.3%NA0.2%56.5%2%-
BVPS (₹) 384.2384.9370.9304384.2347.9393.4437.9507.9579.4379
Adj Net
Profit
9.65-4.63.52.3-14.217.717.827.828.328
Cash Flow from Ops. 611.2-26.67.2-75.65.616.97.56.63.7-
Debt/CF from Ops. 0000000000-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales -6%-12.8%-8.8%9.7%
Adj EPS 12.8%65%17%2%
BVPS4.7%8.6%13.8%14.1%
Share Price - - - -

Key Financial Parameters

Performance Ratio Colour Code Guide

Dec'10Dec'11Dec'12Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20TTM
Return on
Equity %
6.63.4-3.131.6-1012.31115.113.415.2
Op. Profit
Mgn %
5-0.2-6.8-1.7-4-17.215.718.221.127.5-6.5
Net Profit
Mgn %
5.12.4-2.11.61.1-912.314.427.925.925.9
Debt to
Equity
0000000000-
Working Cap
Days
256244251198281410438410347348132
Cash Conv.
Cycle
1445-64061-12-116-71-60100

Recent Performance Summary

No data to display

Return on Equity has declined versus last 3 years average to %

Sales growth has been subdued in last 3 years %

Net Profit has been subdued in last 3 years %

Sales growth is not so good in last 4 quarters at %

Latest Financials - Fulford (India) Ltd.

Standalone Consolidated
TTM EPS (₹) 72.7 72.7
TTM Sales (₹ Cr.) 109 109
BVPS (₹.) 379 579.3
Reserves (₹ Cr.) 144 222
P/BV 6.23 4.08
PE 32.51 32.51
From the Market
52 Week Low / High (₹) 2350.00 / 2363.00
All Time Low / High (₹) 51.00 / 2365.00
Market Cap (₹ Cr.) 921
Equity (₹ Cr.) 3.9
Face Value (₹) 10
Industry PE 78.3

Management X-Ray of Fulford India:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Fulford India

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSDec'10Dec'11Dec'12Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20
Sales190.21214.20215.37269.64217.07157.72143.91123.0999.73109.36
Operating Expenses 180.63219.10230.52274.29225.72184.77121.33100.7278.6879.28
Manufacturing Costs3.864.293.021310.751.846.340.8643.04
Material Costs97.13111.39118.12134.63116.5183.2758.9343.9636.6136.03
Employee Cost 33.1439.9745.0950.5043.2541.0522.9117.3912.7720.85
Other Costs 46.5063.4564.2976.1555.2158.6133.1538.5125.3019.37
Operating Profit 9.57-4.90-15.15-4.65-8.65-27.0522.5822.3821.0530.08
Operating Profit Margin (%) 5.0%-2.3%-7.0%-1.7%-4.0%-17.1%15.7%18.2%21.1%27.5%
Other Income 9.739.379.6512.5414.236.176.707.0519.029.06
Interest 0.320.070.040.950.190.050.050.020.260.29
Depreciation 1.591.711.701.520.600.170.370.370.330.09
Exceptional Items 0000000000
Profit Before Tax 17.392.70-7.255.434.79-21.1028.8529.0439.4738.76
Tax 5.340.86-2.260.962.48-6.9611.1211.2211.6810.43
Profit After Tax 12.061.84-4.994.472.31-14.1417.7317.8327.7928.34
PAT Margin (%) 6.3%0.9%-2.3%1.7%1.1%-9.0%12.3%14.5%27.9%25.9%
Adjusted EPS (₹)30.94.7-12.811.55.9-36.345.545.771.372.7
Dividend Payout Ratio (%)15%74%-8%17%25%0%0%2%1%0%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSDec'10Dec'11Dec'12Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20

Equity and Liabilities

Shareholders Fund 149.85150.11144.66148.21149.82135.68153.41170.77198.09225.96
Share Capital 3.903.903.903.903.903.903.903.903.903.90
Reserves 145.95146.21140.76144.31145.92131.78149.51166.87194.19222.06
Minority Interest0000000000
Debt0000000000
Long Term Debt0000000000
Short Term Debt0000000000
Trade Payables33.5349.2439.9946.5222.1821.0635.5826.2615.6719.10
Others Liabilities 77.2082.6979.7978.1085.9681.9792.618.827.994.61
Total Liabilities 260.58282.03264.44272.83257.96238.71281.60205.85221.75249.67

Fixed Assets

Gross Block11.1810.9911.099.819.499.699.106.966.744.99
Accumulated Depreciation5.666.838.428.618.868.558.326.536.644.97
Net Fixed Assets5.524.162.681.190.621.140.780.430.100.02
CWIP 0000000000
Investments 0000000000
Inventories32.9944.7144.7035.8055.9627.042714.15122.12
Trade Receivables11.299.236.463.1820.219.0710.293.393.1617.60
Cash Equivalents 114.38131.44111.36129.3965.7374.6397.92111.80125.89137.04
Others Assets96.4092.4999.25103.26115.44126.83145.6076.0980.6192.90
Total Assets 260.58282.03264.44272.83257.96238.71281.60205.85221.75249.67

Cash Flow

(All Figures are in Crores.)
PARTICULARSDec'10Dec'11Dec'12Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20
Cash Flow From Operating Activity 6.0111.18-26.629-75.635.6116.897.466.613.65
PBT 17.392.70-7.255.434.79-21.1028.8529.0439.4738.76
Adjustment -3.18-4.48-9.20-8.25-11.93-5.76-6.20-6.09-18.26-8.29
Changes in Working Capital 2.0717.84-7.1520.26-58.9245.2612.61-1.322.43-5.96
Tax Paid -10.28-4.87-3.02-8.45-9.56-12.79-18.37-14.18-17.04-20.86
Cash Flow From Investing Activity 17.967.828.4710.4513.08-31.0141.53-43.46-2.9669.78
Capex -1.51-0.35-0.20-0.03-0.03-0.610.030.120-0.01
Net Investments 150000035.25-50.35-10.6561.51
Others 4.478.178.6710.4813.11-30.396.256.777.698.28
Cash Flow From Financing Activity -2.33-2.11-1.63-1.41-1.11-0.73-0.10-0.46-0.74-0.77
Net Proceeds from Shares 0000000000
Net Proceeds from Borrowing 0000000000
Interest Paid -0.29-0.07-0.04-0.95-0.19-0.05-0.05-0.02-0.26-0.29
Dividend Paid -1.74-1.75-1.36-0.40-0.79-0.56-0.04-0.36-0.40-0.40
Others -0.30-0.29-0.22-0.06-0.13-0.120-0.08-0.08-0.08
Net Cash Flow 21.6316.90-19.7818.04-63.65-26.1258.33-36.462.9072.66
PARTICULARSDec'10Dec'11Dec'12Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20
Ratios
ROE (%)8.321.23-3.393.051.55-9.9112.271115.0713.36
ROCE (%)12.231.85-4.894.363.34-14.752017.9321.5518.42
Asset Turnover Ratio0.760.790.7910.820.640.550.510.470.46
PAT to CFO Conversion(x)0.56.08N/A2.01-32.74N/A0.950.420.240.13
Working Capital Days
Receivable Days2517137203425201235
Inventory Days66667654779668614824
Payable Days11613613811710895175257209176

Fulford (India) Ltd Stock News

Fulford (India) Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Fulford India on 01-Jan-1970 05:30 is ₹0.00.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 01-Jan-1970 05:30 the market cap of Fulford India stood at ₹921.2.
The latest P/E ratio of Fulford India as of 01-Jan-1970 05:30 is 32.51.
The latest P/B ratio of Fulford India as of 01-Jan-1970 05:30 is 6.23.
The 52-week high of Fulford India is ₹2,363 and the 52-week low is ₹2,350.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Fulford India is ₹109.4 ( Cr.) .

About Fulford (India) Ltd

Fulford was incorporated in 1948. It was then registered under the name C E Fulford and was 100% owned by C E Fulford Limited of UK. Until 1968, the company was engaged in the business of manufacturing and marketing pharmaceutical consumer products, including cough tablets and herbal ointments, marketed under the trademarks – PEPS and ZAMBUK respectively.

The company offers medicines for the treatment of allergy & respiratory, arthritis & immunology, cancer therapies, cardiovascular, hepatitis, sun care, etc.

Fulford is a subsidiary of Schering-Plough Corporation, USA, a leading research-based company, engaged primarily in the discovery, development, manufacturing and marketing of pharmaceutical and health care products worldwide.

On July 1, 1968, Schering-Corporation, USA, an international research-based pharmaceutical company acquired 100% ownership of C. E. Fulford Limited, UK. Subsequently, a manufacturing plant was set up at Andheri for the manufacture of pharmaceutical products. The company’s operations commenced with the introduction of an antibiotic injection under the brand name GARAMYCIN and an antifungal skin solution under the brand name TINADERM.

In 1971, Schering Corporation merged with Plough Inc., a mass merchandiser of popular consumer products and Schering-Plough Corporation was formed. Schering-Plough has its headquarters and executive offices at New Jersey, USA.

 In August 1981, the company changed its status from a private company to a public company and from January 1, 1982 diluted the foreign shareholding from 100% to 40%, to fall in line with the prevailing government policy. The shares of Fulford are listed on the Bombay Stock Exchange. There have been three bonus issues in the ratios of 1:1 since the public issue of shares.

It is committed to earning the trust of doctors, patients and customers every day. Their colleagues worldwide believe that trust is not easily granted, and that is the reason they focus each day on becoming a champion for their stakeholders. During the past few years, the company has been building a new kind of health care company. Their scientists are earning trust through the discovery and development of innovative, science-based medicines and services that improve the health and well-being of people around the world.

The test of  being a true champion is to never give up and to passionately strive for even better outcomes. From their perspective as a health care company, that means helping people live better and live longer

Fulford offers medicines in the following areas:

  • Allergy & Respiratory
  • Arthritis & Immunology 
  • Cancer Therapies 
  • Cardiovascular 
  • Hepatitis 
  • Sun Care  
  • Skin Disorders 
  • Systemic Anti Infective 

Key Products of the company include:

Quadriderm RF, Dipsalic F, Elocon, Alaspan, Netromyicin, Remicade, Viraferon Peg, Integrilin etc.

Read More Read Less
You have 0 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.